IE 11 is not supported. For an optimal experience visit our site on another browser.

FDA Warns Kim Kardashian About Instagram Drug Endorsement

The FDA wasn't amused when celebrity Kim Kardashian endorsed a drug on Instagram.
Get more newsLiveon
/ Source:

Kim Kardashian may be famous for her selfies, but the Food and Drug Administration wasn't a fan of her latest one.

An Instagram picture featuring Kardashian, morning sickness drug Diclegis and accompanying text promoting the drug's benefits garnered more than 450,000 "likes" but brought about a formal FDA warning letter for the drug's manufacturer.

Kim Kardashian's recalled Instagram post advertising morning sickness drug Diclegis.
Kim Kardashian's recalled Instagram post advertising morning sickness drug Diclegis.CNBC

Part of the letter says, "The social media post is misleading because it presents various efficacy claims for Diclegis, but fails to communicate any risk information."

Read more at CNBC: Kermit and Miss Piggy are the latest power couple to split

The posts promoting the drug have since been taken down, but Kardashian, who was paid to promote the drug, originally claimed it made her feel "a lot better and most importantly, it's been studied and there was no increased risk to the baby."Duchesnay, the pharmaceutical company behind the drug, told CNBC that while Kim was paid to promote her experience with the drug she had found it on her own accord through her family OB-GYN. The company said it would take quick action in responding to the FDA's letter.

Read more at CNBC: What's it like to be a Victoria Secret model?

"Duchesnay USA takes its regulatory responsibilities very seriously, and acknowledges that its communications, including in social media as in this particular instance, need to be in accordance with applicable rules and regulations," the company said.The FDA warning letter also requests Duchesnay offer corrections to the claims "using the same media" for the same audience. That could mean a revised selfie for Kim's 42.4 million followers.

Kardashian did not immediately respond to a request for comment from CNBC.